Skip to main content
European Commission logo print header

Targeting chromatin in cancer: histone deacetylases and differentiation therapy of acute myeloid leukemias (CHROMATIN AND CANCER)

Objective

Acetylation/deacetylation by histone acetylases (HAT) and deacetylases (HDAC) regulates gene transcription and specific functions, such as tumour suppression by p53. Abnormalities of HAT or HDAC are frequently found in tumours. Targeting of HDAC by small compounds is effective in the differentiation treatment of a small subset of leukaemia. We aim to determine whether HDACs are suitable general targets for cancer drug discovery. We will characterize the mechanisms of activities of HDAC/HAT in normal and cancer cells, and screen tumours with a panel of HDAC inhibitors. Our experimental approaches range from biochemistry, to molecular biology, to post-genomics (proteomics and nanotechnology), and include the functional validation of compounds and demonstrated mechanisms in animal model systems and tumour samples. Final objective is the design of differentiation treatment protocols for leukaemia and myelodysplastic syndromes.

Call for proposal

Data not available

Coordinator

ISTITUTO EUROPEO DI ONCOLOGIA SRL
EU contribution
No data
Address
Via Ripamonti 435
20141 MILANO
Italy

See on map

Total cost
No data

Participants (9)